InvestmentJun 3, 2026, 04:03 PM
Jade Biosciences Announces Proposed Public Offering of Common Stock
AI Summary
Jade Biosciences, Inc. announced its intention to conduct an underwritten public offering of its common stock or pre-funded warrants. The company plans to use the net proceeds from this offering, along with existing cash, to fund clinical trials, preclinical studies, manufacturing, and additional research and development activities. Jefferies, TD Cowen, and UBS Investment Bank are serving as joint book-running managers for the proposed offering.
Key Highlights
- Intends to offer common stock or pre-funded warrants in a proposed underwritten public offering.
- Underwriters granted a 30-day option to purchase up to an additional 15% of the securities.
- Net proceeds to fund clinical trials, preclinical studies, and manufacturing for programs.
- Funds also allocated for additional research and development activities and general corporate purposes.
- Jefferies, TD Cowen, and UBS Investment Bank are acting as joint book-running managers.
- Offering is pursuant to a shelf registration statement on Form S-3, effective May 15, 2026.
Price Impact
More from JBIO